Lonza
NEWS
Albert Baehny, chairman of the board of directors, said the company looks forward to the coming challenges of 2020, including the naming of a new CEO.
Results demonstrating the performance of the eCHO™ Medium will be presented at the 2019 PEGS Europe and Antibody Engineering and Therapeutics conferences
Lonza announced that Marc Funk, CEO, will leave the Company for personal reasons. The Board of Directors also announced that Albert Baehny, Chairman, will take on the additional responsibility of Chief Executive Officer on an ad interim basis until a permanent successor is found.
Free Lonza webinar to discuss the benefits of a collaborative approach to implementing an Electronic Batch Record Platform
Lonza’s Ibex™ Design planned to take Genmab’s pre-clinical candidates from gene to potential IND within 12 months
The two companies will partner on the process development, analytical development and large-scale manufacturing for late-stage clinical and commercial supply.
Lonza has partnered with Nephron Pharmaceuticals Corporation to implement Lonza’s next-generation MODA-ES™ EBR Platform to streamline manufacturing compliance reporting
Double-digit sales growth delivered by Pharma Biotech & Nutrition (LPBN) segment
Expansion to bioconjugation facility in Visp, Switzerland to meet increasing clinical, launch and commercial market demand
JOBS
IN THE PRESS